Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens
Breast Cancer Metastatic
DRUG: Sacituzumab Govitecan with pegfilgrastim
To evaluate the incidence of grade ≥3 neutropenia, Incidence of grade ≥3 neutropenia after 2 cycles of treatment, At the end of Cycle 2 (each cycle is 21 days)
Safety and tolerability of the study regimen, Incidence of AEs, Up to 5 years|Objective Response Rate, The percentage of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response as assessed by investigator per RECIST v1.1, Up to 5 years|Progression Free Survival, Up to 5 years|Overall Survival, The time until defined by date of all-cause mortality from the date of 1st infusion The time until defined by date of all-cause mortality from the date of 1st infusion, Up to 5 years
▪ Sacituzumab Govitecan group

- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9